60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) announced its earnings results on Friday. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.52), FiscalAI reports. The firm had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.44 million.
60 Degrees Pharmaceuticals Price Performance
NASDAQ SXTP traded down $0.07 during trading hours on Friday, reaching $1.39. The company’s stock had a trading volume of 21,402 shares, compared to its average volume of 3,044,849. The company’s 50-day moving average is $1.84 and its two-hundred day moving average is $3.01. 60 Degrees Pharmaceuticals has a 1-year low of $1.29 and a 1-year high of $14.68. The firm has a market capitalization of $3.67 million, a price-to-earnings ratio of -0.10 and a beta of 2.69.
Analyst Upgrades and Downgrades
SXTP has been the subject of a number of recent research reports. Wall Street Zen downgraded 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, April 12th. HC Wainwright boosted their target price on 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. Ascendiant Capital Markets lowered their price objective on 60 Degrees Pharmaceuticals from $11.20 to $4.20 and set a “buy” rating for the company in a research report on Thursday, April 9th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $14.10.
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.
See Also
- Five stocks we like better than 60 Degrees Pharmaceuticals
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
